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Background and Purpose. Intravenous thrombolysis using tissue plasminogen activator is safe and probably eﬀective in patients
>80 years old. Nevertheless, its safety has not been specifically addressed for the oldest old patients (≥85 years old, OO). We
assessed the safety and eﬀectiveness of thrombolysis in this group of age. Methods. A prospective registry of patients treated with
intravenous thrombolysis. Patients were divided in two groups (<85 years and the OO). Demographic data, stroke aetiology and
baseline National Institute Health Stroke Scale (NIHSS) score were recorded. The primary outcome measures were the percentage
of symptomatic intracranial haemorrhage (SICH) and functional outcome at 3 months (modified Rankin Scale, mRS). Results. A
total of 1,505 patients were registered. 106 patients were OO [median 88, range 85–101]. Female sex, hypertension, elevated blood
pressure at admission, cardioembolic strokes and higher basal NIHSS score were more frequent in the OO. SICH transformation
rates were similar (3.1% versus 3.7%, P = 1.00). The probability of independence at 3 months (mRS 0–2) was lower in the OO
(40.2% versus 58.7%, P = 0.001) but not after adjustment for confounding factors (adjusted OR, 0.82; 95% CI, 0.50 to 1.37;
P = 0.455). Three-month mortality was higher in the OO (28.0% versus 11.5%, P < 0.001). Conclusion. Intravenous thrombolysis
for stroke in OO patients did not increase the risk of SICH although mortality was higher in this group.
1. Introduction
Later years of life are marked by increased vulnerability
to some events, such as stroke. The incidence of stroke
increases exponentially with age. Diﬀerent epidemiological
studies have shown a rapid increase in the incidence of
stroke, with that rate doubling each consecutive decade after
55 years of age and with stroke occurring in more than
half of people over 75 years old [1]. People 85 years old or
older, often known as the oldest old (OO) [2, 3], are the
fastest growing segment of the older American population
[4]. By 2050, it is estimated that there will be more than 55
million nonagenarians worldwide [5], and very old patients
will likely constitute the majority of stroke victims [6–8].
The Oxford Vascular Study indicated a 12-fold increase
in the incidence of stroke in the OO, compared with the
younger population [9]. The OO also have higher mortality,
morbidity, disability, and greater functional impairment
compared with younger patients [10–12].
Intravenous thrombolytic treatment with recombinant
tissue plasminogen activator (IV-tPA) is the only medical
therapy currently available for acute ischaemic stroke, reduc-
ing the risk of death or dependence [13–15]; however, the
European Medicines Evaluation Agency has not approved
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thrombolysis for patients over 80 on the basis that there is
no experience with this particular segment, as they have been
excluded or underrepresented inmajor clinical trials. Only 42
patients (7%) over 80 years old were included in the National
Institute of Neurological Disorders and Stroke (NINDS) trial
[13, 16]. In a subgroup analysis of this trial, there was no
correlation between symptomatic intracerebral haemorrhage
(SICH) and age [13, 17]. More recently, several studies have
demonstrated the safety of IV-tPA in patients over 80 years of
age [18–25]. Nevertheless, it is not as well known for the OO
because the cases covered in these series either only includes
a small percentage from this particular group or the authors
did not perform specific analyses [24, 26–28].
Herein, we present a review of our experience with
IV-tPA in very old patients. We evaluate its safety and
eﬀectiveness in comparison with its use in younger patients.
2. Material andMethods
Study design: observational analysis of a multicentre stroke
registry with prospective inclusion of consecutive acute
ischemic stroke patients treated with IV-tPA at five stroke
units (SU) at the Madrid Stroke Network, from January 2003
to December 2010 [29].
Treatment: patients who fulfilled criteria for intravenous
thrombolysis received IV-tPA in a standard 0.9mg/kg dose
within three hours of stroke onset. Since the publication
of the ECASS-III and data from the SITS registry, patients
have been treated within the 4.5-hour time window [14,
30]. Patients or surrogates (in cases of patients lacking
capacity due to severity of stroke or other reasons) signed
an informed consent document prior to IV-tPA, which
specifically included consent for the inclusion of clinical data
in a database. This database was approved by Ramo´n y Cajal
University Hospital Ethics Committee for Clinical Research.
3. Clinical Assessment
Stroke onset was defined as the last time the patient was
known to be without neurological deficit. On admission,
neurological examination and cranial computed tomography
(CT) scan were performed. Stroke severity was assessed,
using baseline National Institutes of Health Stroke Scale
(NIHSS) score, at 24 hours and at 7 days after treatment.
NIHSS-certified neurologists performed all evaluations.
Basal mRS was defined on mRS score before stroke (esti-
mated from the information provided by family members
living with the patient) [31]. Covariables included age, sex,
stroke risk factors, and stroke aetiology, as well as the blood
glucose level and the systolic arterial blood pressure (BP) on
admission. Elevated BP was defined as a BP > 185/110mm
Hg. Previous antithrombotic treatments (antiplatelet agents
or anticoagulants) were recorded. Eﬀective anticoagulant
treatment was considered as a contraindication for IV-
tPA. The following intervals were recorded: stroke onset-
to-door, stroke onset-to-treatment, and door-to-treatment.
A posttreatment CT scan was performed on all patients
after 24 hours (range, 22–36 hours) or earlier in the case of
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Figure 1: Distribution of patients according to age (Oldest Old
group).
neurological deterioration. In addition, Magnetic Resonance
Imaging (MRI) was used in selected cases. Cerebral haem-
orrhages were classified according to the Safe Implemen-
tation of Thrombolysis in Stroke-Monitoring Study (SITS-
MOST) [25] classification (HI1, HI2, PH1, PH2, PHr1,
PHr2). Symptomatic intracranial haemorrhage (SICH) was
defined as local or remote type 2 parenchymal haemorrhages
combined with a neurological deterioration of 4 or more
points from baseline on the NIHSS score, from the lowest
NIHSS value between baseline and 24 hours, or leading to
death [30]. Asymptomatic intracranial haemorrhage (AICH)
was defined as the presence of a haemorrhage on the CT scan
without neurological deterioration.
Functional outcomewas rated using themodified Rankin
scale (mRs) after 90 days, and functional outcomes were
classified as follows: favourable (0-1), independent (0–2),
moderate disability, severe disability or death (3–6), and case
fatality (6). Causes of death were classified as follows: stroke,
SICH,myocardial infarction, pulmonary thromboembolism,
pneumonia, other vascular causes, and other causes.
4. Statistical Analysis
Analyses were performed using the Statistical Package for
the Social Sciences (SPSS) versus 17 (SPSS Inc., Somers,
NY, USA). Descriptive analyses were completed using the
median and percentiles (P25 and P75) for quantitative
variables and the frequency and percentage for qualitative
variables. Comparisons were made according to age (OO
versus <85 years old) with univariate analyses using the
Pearson’s chi-square test and the Mann-Whitney U-test,
as appropriate. Three logistic regression models were con-
structed to estimate the association between age ≥ 85 years
and mortality, haemorrhagic transformation and mRs at 3
months, respectively, adjusting for other possible confounder
variables (sex, basal NIHSS score, cardioembolic aetiology,
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prior antiplatelet or anticoagulant therapy, stroke onset-to-
treatment time, basal mRS and elevated BP in the acute
phase of stroke). Odds ratios (OR) and 95% confidence
intervals (CI) were estimated. The existences of interactions
between the possible confounder variables and age≥ 85 years
were also explored. After determining whether an interaction
existed or not, the presence of confounders was also studied.
A backward elimination strategy was used. Factors were
considered to be confounding if the coeﬃcient of the variable
age ≥ 85 years was modified by more than 10% of its value
after removing the suspect variable. All values were based
on 2-tailed statistical analyses, with values of P < 0.05
considered statistically significant.
5. Results
A total of 1,505 patients were treated with IV-tPA and
included in the database. One hundred and six (7%) were
OO (median 88; range 85–101) (Figure 1). Table 1 shows
baseline and demographic data, stroke aetiology, and degree
of neurological severity of both groups. The OO group
had a significantly higher proportion of females (68.9%
versus 45.1%, P < 0.001) and a higher incidence of arterial
hypertension (78.6% versus 60.4%, P < 0.001), elevated
BP on admission (26.7% versus 14.8%, P = 0.001), atrial
fibrillation (30.1% versus 17.4%, P = 0.001), and prior
antiplatelet therapy (33.0% versus 20.2%, P = 0.002).
Patients in the OO group were also less likely to smoke (1%
versus 23.3%, P < 0.001). Stroke severity was higher in
the OO group (median baseline NIHSS score 16 versus 13,
P = 0.001). The stroke onset-to-door time in the OO group
was significantly longer (85min versus 75min, P = 0.049),
but neither the door-to-treatment time nor the stroke-onset-
to-treatment times diﬀered between groups. Cardioembolic
stroke was significantly more frequent in the OO group
(61.7% versus 42.1%, P = 0.003).
Postbasal functional outcome values, up to three months
after stroke, were obtained for the vast majority of patients
(1,413, 93.8%). Only 79 (5.65%) and 13 (12.26%) patients of
each group were lost to follow up. Mortality was significantly
higher in the OO group (28.0% versus 11.5%, P <
0.001). The cause of death diﬀered between groups, being
pneumonia the leading cause of death (48%) in the OO
group. The number of patients with a favourable (31.2%
versus 45%, P = 0.009) or an independent (40.2% versus
58.7%, P = 0.001) outcome was significantly smaller in
the OO group (Figure 2). There were no diﬀerences in the
proportion of SICH between the two groups (3.1% in the
OO versus 3.7% in the group of <85 years old; p=1.000) or
AICH (16% versus 16%, P = 0.083) (Table 2).
A multivariate analysis was used to compare the mor-
tality, haemorrhagic transformation, and functional inde-
pendence (mRs 0–2) at 3 months between the two groups,
adjusting for other possible confounding factors. Elevated
BP on admission, baseline NIHSS score, basal mRs, and
prior antiplatelet therapy were identified as confounding
factors bymultiple regression analysis (see Table 3). After this
adjustment, there were no diﬀerences in the proportion of
haemorrhagic transformation in both groups (adjusted OR,
0.74; 95% CI, 0.43 to 1.30; P = 0.296), and there was no
statistically significant diﬀerence in functional independence
in the OO group (adjusted OR, 0.82; 95% CI, 0.50 to 1.37;
P = 0.455). Mortality remained higher among the OO group
(adjusted OR, 2.04; 95% CI, 1.18 to 3.55; P = 0.011).
6. Discussion
Some of the reasons clinical trials with IV-tPA excluded older
patients included impaired rate of tPA clearance, increased
rate of cardioembolic strokes, and the presence of amyloid
angiopathy that could increase the rate of SICH [6, 32].
Mortality rates and the proportion of moderate or severe
functional impairment after an acute ischaemic stroke are
higher in the elderly [12, 33, 34]. In general, the series of
patients older than 80 years treated with IV-tPA have had
increasedmortality, and the proportion of patients with good
functional outcome was smaller in comparison with younger
patients [6, 7, 18–21]. Furthermore, Sarikaya et al. [27]
have suggested less favourable outcomes in nonagenarians
as compared with octogenarians after IV-tPA. However, very
recently, the Safe Implementation of Treatment in Stroke-
International Stroke Thrombolysis Register (SITS-ISTR) has
provided the largest amount of data on the safety and
outcome in thrombolysis in patients >80 years of age. This
group concluded that these patients had a similar rate of
SICH, and the higher mortality and the poorer functional
outcomes were consistent with the overall worse prognosis
seen in the natural history of this age group; therefore,
patients in this age group are appropriate candidates for
thrombolysis [25]. Moreover, this group performed an
adjusted controlled comparison of outcomes between stroke
patients who underwent thrombolysis through the SITS-
ISTR, with untreated stroke patients from neuroprotection
trials held within the Virtual International Stroke Trials
Archive (VISTA). Although increasing age is associated with
a poorer outcome, the association between thrombolysis
treatment and improved outcome is maintained in very old
patients [25]. Mateen et al. [26] compared the outcomes
of thrombolysis in octogenarians and nonagenarians and
found that there were no significant diﬀerences in functional
outcome or rate of SICH.
Our analysis of prospectively collected data indicates
that a small cohort of very old patients were treated using
thrombolysis (7% of all patients treated). One possible
explanation is that our registry started in 2004, when
information about IV-tPA in old patients was scarce. The
majority (78.3%) of older patients were treated in the last
two years of the registry. Alshekhlee et al. [23] also found
very low rates of thrombolysis among very old patients and
a trend of increasing IV-tPA use in this age segment over the
recent years.
Our results show that a large proportion of OO patients
treated with IV-tPA were functionally independent at 90
days (40.2%), although this figure was significantly higher in
the group of patients <85 years (58.7%). Furthermore, the
mortality rate was higher in the elderly group (28%). As we
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Table 1: Baseline characteristics and aetiology.
<85 years old Oldest Old Group comparison
P value
n (%) 1399 (93) 106 (7)
Age, y-o (median, range) 71 (18–84) 88 (85–101)
Gender
Female, n (%) 630 (45.1) 73 (69.9) <0.001∗
Risk factors
Arterial hypertension, n (%) 837 (60.4) 81 (78.6) <0.001∗
Diabetes mellitus, n (%) 280 (20.2) 14 (13.6) 0.103
Dyslipemia, n (%) 485 (35.2) 29 (28.2) 0.149
Current smoking, n (%) 322 (23.3) 1 (1) <0.001∗
Atrial fibrillation, n (%) 241 (17.4) 31 (30.1) 0.001∗
Prior antiplatelet therapy, n (%) 280 (20.2) 34 (33) 0.002∗
Prior anticoagulation therapy, n (%) 57 (4.1) 7 (6.8) 0.149
Elevated BP (>185/110mgHg) on admission n (%) 200 (14.8) 27 (26.7) 0.001∗
Blood glucose on admission (mmol/dL), median (IQR) 119 (102–144) 118 (10.5–151.5) 0.415
Baseline NIHSS, median (IQR) 13 (8–18) 16 (10–21) <0.001∗
Time (min), median (IQR)
Stroke onset-to-door time 75 (55–110) 85 (64–115) 0.049∗
Door-to-treatment time 58 (42–76) 58 (45–74) 0.808
Stroke onset-to-treatment time 144.5 (115–173.7) 142.5 (120–186.2) 0.265
Aetiology, n (%)
Atherothrombotic 325 (24.2) 19 (20.2) ns
Cardioembolic 565 (42.1) 58 (61.7) 0.025∗
Lacunar 60 (4.5) 1 (1.1) ns
Other determined aetiology 72 (5.4) 0 ns
Undetermined aetiology 321 (23.9) 16 (17) ns
NIHSS: National Institutes of Health Stroke Scale; IQR: interquartile range; BP: blood pressure. Statistical significance ∗P < 0.005.
mRS after 90 days in <85 y-o
mRS after 90 days in OO
mRS = 0
mRS = 1
mRS = 2
mRS = 3
mRS = 4
mRS = 5
mRS = 6
27.6% 17.4% 13.6% 13.3% 13.1% 3.3% 11.7%
15.1% 16.1% 8.6% 11.8% 12.9% 7.5% 28%
Scores on modified Rankin scale
Figure 2: Scores on modified Rankin scale.
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Table 2: Clinical outcome and haemorrhagic complications.
<85 y-o
n = 1399
Oldest Old
n = 106
Group comparison
P value
Patients lost to followup n (%) 79 (5.65) 13 (12.26)
NIHSS score at 24 hours, median (IQR) 6 (2–15) 11 (4–19) <0.001∗
NIHSS score at day 7, median (IQR) 3 (0–11) 6 (1–16.5) 0.005∗
Long-term outcome parameters (day 90)
Favourable outcome (mRS 0-1), n (%) 594 (45) 29 (31.2) 0.009∗
Independent outcome (mRS 0–2), n (%) 772 (58.7) 37 (40.2) 0.001∗
Moderate disability, severe disability, or death (mRS 3–6), n (%) 541 (41.1) 55 (59.8) 0.001∗
Mortality n (%) 155 (11.5) 26 (28) <0.001∗
Causes of death
Ischaemic stroke, n (%) 60 (42.3) 9 (36) ns
SICH, n (%) 16 (11.3) 1 (4) ns
Myocardial Infarction, n (%) 5 (3.5) 1 (4) ns
Pneumonia, n (%) 41 (28.9) 12 (48) ns
Pulmonary thromboembolism, n (%) 1 (0.7) 0 ns
Other vascular causes, n (%) 7 (4.9) 2 (8) ns
Hemorrhagic transformation
AICH, n (%) 201 (16%) 15 (16%) 0.983
SICH, n (%) 48 (3.7) 3 (3.1) 1.000
NIHSS: National Institutes of Health Stroke Scale; mRS: Modified Rankin Scale; IQR: interquartile range. SICH: symptomatic intracranial haemorrhage;
AICH: Asymptomatic intracranial haemorrhage. Statistical significance ∗P < 0.005.
Table 3: Regression analysis.
Univariate analysis Adjusted analysis
OR CI 95% P OR CI 95% P
Mortality OO∗ 2.98 1.84–4.82 <0.001∗ 2.04 1.18–3.55 0.011∗
Haemorrhagic transformation OO† 0.83 0.26–2.73 0.396 0.74 0.43–1.30 0.296
mRs (day 90) OO† 0.47 0.31–0.73 0.001∗ 0.82 0.50–1.37 0.455
∗Adjusted by baseline NIHSS and elevated BP on admission; †Adjusted by baseline NIHSS score, elevated BP on admission and sex. Statistical significance
∗P < 0.005.
can see in our multivariable analysis, the worse functional
recovery can be explained by confounding factors, whereas
mortality was worse in the OO, despite adjustment. We feel
that this fact is due the expected major fragility of this age
group. Pneumonia was the most common cause of death
in the OO group. The rate of SICH in both groups was
similar. We did not find any significant diﬀerences in the
times of management of the stroke inside the hospital, and
only stroke-onset-to-door time was significantly longer when
compared to the total group of the registry.
This study has several limitations. First, it reports the
results of a small cohort of very old patients, and the cohort
was compared with a more numerous cohort of patients < 85
years old. Second, the study is a post hoc analysis of a registry,
and selection bias is an important limitation to the data set.
The decision to administer IV-tPA was made by multiple
diﬀerent treating neurologists, and some factors, not limited
to age and prior functional status, could bias treating very
old patients with IV-tPA. Finally, the main limitation of the
study is the lack of a concurrent untreated control group.
This study supports the use of thrombolytic treatment
for very old patients, with safety results similar to younger
patients. Although OO patients may have a higher mortality
at three months, they still do better than those who do not
receive IV-tPA.
As evidence of safety of thrombolysis in very old is
increasing, more elderly patients are now treated with IV-
tPA. However, reliable evidence on the risk-benefit bal-
ance of intravenous thrombolysis in this age group can
only be evaluated using randomised controlled throm-
bolysis trials, such as the ongoing Third International
Stroke Trial or the Thrombolysis in Elderly Stroke Patients
[35, 36].
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